Kura Oncology, Inc. (KURA)
Largest Insider Buys in Sector
KURA Stock Price History Chart
KURA Stock Performance
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Insider Activity of Kura Oncology, Inc.
Over the last 12 months, insiders at Kura Oncology, Inc. have bought $0 and sold $2.1M worth of Kura Oncology, Inc. stock.
On average, over the past 5 years, insiders at Kura Oncology, Inc. have bought $575,000 and sold $7.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $575,000 was made by Malley Thomas (director) on 2023‑06‑16.
List of Insider Buy and Sell Transactions, Kura Oncology, Inc.
| 2024-05-20 | Sale | Bair Teresa Brophy | Chief Legal Officer | 2,615 0.0034% | $22.15 | $57,916 | -4.93% | |
| 2024-01-30 | Sale | DALE STEPHEN | Chief Medical Officer | 4,825 0.0067% | $21.55 | $103,980 | -0.95% | |
| 2024-01-29 | Sale | Bair Teresa Brophy | Chief Legal Officer | 2,053 0.0027% | $17.80 | $36,544 | +11.53% | |
| 2024-01-29 | Sale | DOYLE THOMAS JAMES | SVP, Finance & Accounting | 2,318 0.003% | $17.80 | $41,262 | +11.53% | |
| 2024-01-29 | Sale | DALE STEPHEN | Chief Medical Officer | 7,158 0.0093% | $17.80 | $127,416 | +11.53% | |
| 2024-01-29 | Sale | FORD KATHLEEN | Chief Operating Officer | 1,496 0.0019% | $17.80 | $26,630 | +11.53% | |
| 2024-01-24 | Sale | WILSON TROY EDWARD | President and CEO | 84,107 0.1166% | $20.23 | $1.7M | +5.39% | |
| 2023-06-16 | Malley Thomas | director | 50,000 0.0781% | $11.50 | $575,000 | +13.75% | ||
| 2023-01-27 | Sale | DALE STEPHEN | Chief Medical Officer | 9,225 0.0138% | $13.88 | $128,033 | -19.28% | |
| 2023-01-27 | Sale | FORD KATHLEEN | Chief Operating Officer | 1,821 0.0027% | $13.89 | $25,294 | -19.28% | |
| 2023-01-27 | Sale | FLOWERS KIRSTEN | CCO & Chief Strategy Officer | 1,906 0.0029% | $13.89 | $26,474 | -19.28% | |
| 2023-01-27 | Sale | DOYLE THOMAS JAMES | SVP, Finance & Accounting | 1,548 0.0023% | $13.89 | $21,502 | -19.28% | |
| 2021-03-15 | Sale | FORD KATHLEEN | Chief Operating Officer | 6,250 0.0095% | $29.43 | $183,951 | -36.81% | |
| 2020-12-15 | Sale | FORD KATHLEEN | Chief Operating Officer | 9,375 0.0161% | $40.60 | $380,667 | -46.25% | |
| 2020-11-10 | Sale | FORD KATHLEEN | Chief Operating Officer | 6,250 0.0107% | $39.43 | $246,438 | -37.05% | |
| 2020-10-08 | Sale | WILSON TROY EDWARD | President and CEO | 157,106 0.2753% | $34.00 | $5.34M | -16.38% | |
| 2020-10-07 | Sale | WILSON TROY EDWARD | President and CEO | 99,900 0.1621% | $32.00 | $3.2M | -17.58% | |
| 2020-10-06 | Sale | WILSON TROY EDWARD | President and CEO | 100 0.0002% | $32.00 | $3,200 | -10.97% | |
| 2020-09-15 | Sale | FORD KATHLEEN | Chief Operating Officer | 6,250 0.0115% | $29.43 | $183,938 | +1.34% | |
| 2020-09-14 | Sale | WILSON TROY EDWARD | President and CEO | 196,980 0.3454% | $28.82 | $5.68M | -1.48% |
Insider Historical Profitability
| Bair Teresa Brophy | Chief Legal Officer | 68979 0.0929% | $20.60 | 0 | 2 | |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | 48093 0.0648% | $20.60 | 0 | 2 | |
| DALE STEPHEN | Chief Medical Officer | 38817 0.0523% | $20.60 | 0 | 3 | |
| FORD KATHLEEN | Chief Operating Officer | 21602 0.0291% | $20.60 | 0 | 7 | |
| WILSON TROY EDWARD | President and CEO | 559 0.0008% | $20.60 | 0 | 13 | |
| EcoR1 Capital Fund Qualified, L.P. | 10 percent owner | 4408097 5.9351% | $20.60 | 8 | 1 | +14.44% |
| GUALBERTO ANTONIO | Head of Development & CMO | 339973 0.4577% | $20.60 | 0 | 1 | |
| Malley Thomas | director | 139557 0.1879% | $20.60 | 2 | 0 | <0.0001% |
| FLOWERS KIRSTEN | CCO & Chief Strategy Officer | 20605 0.0277% | $20.60 | 0 | 1 | |
| GRASSO MARC | CFO, CBO | 0 0% | $20.60 | 0 | 4 |
Institutional Investor Ownership
| Suvretta Capital Management, LLC | $150.8M | 9.28 | 7.07M | +1.78% | +$2.63M | 6.36 | |
| BlackRock | $147.16M | 9.06 | 6.9M | -5.69% | -$8.88M | <0.01 | |
| Ecor1 Capital Llc | $123.86M | 7.62 | 5.81M | 0% | +$0 | 3.15 | |
| Deerfield Management | $115.43M | 7.1 | 5.41M | +1.86% | +$2.11M | 2.23 | |
| Bvf Inc Il | $102.09M | 6.28 | 4.79M | -35.09% | -$55.18M | 0.75 | |
| State Street | $89.59M | 5.51 | 4.2M | +43.74% | +$27.26M | <0.01 | |
| The Vanguard Group | $86.73M | 5.34 | 4.07M | +0.7% | +$601,761.96 | <0.01 | |
| Avoro Capital Advisors Llc | $82.12M | 5.05 | 3.85M | +29.2% | +$18.56M | 0.98 | |
| Paradigm BioCapital Advisors LP | $66.88M | 4.12 | 3.14M | +148.28% | +$39.94M | 2.43 | |
| Holocene Advisors, LP | $51.99M | 3.2 | 2.44M | 0% | +$0 | 0.19 | |
| Armistice Capital Llc | $43.68M | 2.69 | 2.05M | -7.91% | -$3.75M | 0.52 | |
| Artal Group S A | $40.95M | 2.52 | 1.92M | +8.59% | +$3.24M | 0.22 | |
| GOLDEN CAPITAL MANAGEMENT LLC | $39.46M | 2.43 | 1.85M | 0% | +$0 | 22.92 | |
| Geode Capital Management | $36.42M | 2.24 | 1.71M | +3.1% | +$1.09M | <0.01 | |
| Franklin Templeton Investments | $33.6M | 2.07 | 1.58M | +16.37% | +$4.73M | 0.01 | |
| Commodore Capital, LP | $32.53M | 2 | 1.52M | +22.19% | +$5.91M | 2.29 | |
| Tcg Crossover Management Llc | $30.37M | 1.87 | 1.42M | 0% | +$0 | 0.05 | |
| Dimensional Fund Advisors | $29.08M | 1.79 | 1.36M | -31.89% | -$13.62M | 0.01 | |
| Morgan Stanley | $28.95M | 1.78 | 1.36M | +1.99% | +$565,373.09 | <0.01 | |
| Assenagon Asset Management S.A. | $24.61M | 1.52 | 1.15M | 0% | +$0 | 0.07 | |
| Boxer Capital, LLC | $21.33M | 1.31 | 1M | New | +$21.33M | 1.07 | |
| Prosight Management Lp | $20.48M | 1.26 | 960,000 | +1.05% | +$213,300.00 | 5.7 | |
| Goldman Sachs | $16.76M | 1.03 | 785,876 | +47.84% | +$5.42M | <0.01 | |
| Affinity Asset Advisors | $15.58M | 0.96 | 730,492 | +281.39% | +$11.5M | 2.77 | |
| Northern Trust | $14.81M | 0.91 | 694,346 | -2.18% | -$330,060.42 | <0.01 | |
| Candriam S C A | $13.89M | 0.86 | 651,417 | +20.32% | +$2.35M | 0.09 | |
| Sphera Fund | $13.03M | 0.8 | 610,826 | -13.15% | -$1.97M | 2.15 | |
| Charles Schwab | $12.77M | 0.79 | 598,724 | +3.23% | +$399,660.21 | <0.01 | |
| Susquehanna International Group | $12.69M | 0.78 | 594,879 | +819.68% | +$11.31M | 0.01 | |
| Sofinnova | $10.71M | 0.66 | 501,940 | -69.89% | -$24.86M | 0.02 | |
| Millennium Management LLC | $10.41M | 0.64 | 488,216 | +268.49% | +$7.59M | 0.01 | |
| Bank of America | $10.25M | 0.63 | 480,622 | -36.03% | -$5.77M | <0.01 | |
| JPMorgan Chase | $9.27M | 0.57 | 434,396 | -8.16% | -$823,252.71 | <0.01 | |
| DAFNA Capital Management, LLC | $8.8M | 0.54 | 412,663 | -16.24% | -$1.71M | 2.05 | |
| D. E. Shaw & Co. | $8.32M | 0.51 | 389,902 | +89.62% | +$3.93M | 0.01 | |
| Ally Bridge Group | $7.79M | 0.48 | 365,044 | New | +$7.79M | 4.38 | |
| Verition Fund Management Llc | $7.72M | 0.48 | 361,820 | -22.29% | -$2.21M | 0.08 | |
| Invesco | $6.7M | 0.41 | 314,072 | +354.34% | +$5.22M | <0.01 | |
| Rafferty Asset Management Llc | $6.64M | 0.41 | 311,268 | +105.76% | +$3.41M | 0.02 | |
| Logos Global Management Lp | $6.4M | 0.39 | 300,000 | New | +$6.4M | 0.69 | |
| Algert Global LLC | $5.96M | 0.37 | 279,570 | -16.16% | -$1.15M | 0.24 | |
| Citigroup | $5.8M | 0.36 | 271,896 | +298.48% | +$4.34M | 0.01 | |
| Alethea Capital Management LLC | $5.54M | 0.34 | 259,606 | -25.92% | -$1.94M | 0.35 | |
| BNY Mellon | $5.22M | 0.32 | 244,685 | -6.17% | -$343,498.32 | <0.01 | |
| Renaissance Technologies | $5.12M | 0.32 | 240,200 | -13.63% | -$808,333.47 | 0.01 | |
| UBS | $4.84M | 0.3 | 226,821 | +11.76% | +$509,019.13 | <0.01 | |
| Russell Investments Group Ltd | $4.78M | 0.29 | 224,296 | -0.22% | -$10,409.04 | 0.01 | |
| Nuveen | $4.48M | 0.28 | 210,166 | +5.39% | +$229,361.50 | <0.01 | |
| Two Sigma | $3.79M | 0.23 | 177,650 | New | +$3.79M | 0.01 | |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | $3.55M | 0.22 | 166,526 | New | +$3.55M | 0.34 |